ArticleArchives of medical science : AMS2026
Remnant cholesterol inflammatory index and mortality in cardiovascular-kidney-metabolic syndrome: a national study.
Article in Archives of medical science : AMS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrating measures of remnant cholesterol and inflammation: risky business?Archives of medical science : AMS · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cardiovascular-kidney-metabolic (CKM) syndrome reflects the interconnected progression of metabolic dysfunction, kidney impairment, and cardiovascular disease. The remnant cholesterol inflammatory index (RCII), integrating remnant cholesterol and C-reactive protein, may capture combined metabolic-inflammatory stress, but its association with mortality in CKM populations is unclear. Material and methods: Using NHANES 1999-2018, we included adults aged ≥ 18 years with complete CKM staging and RCII measurements. All-cause mortality was the primary outcome, and cardiovascular mortality the secondary outcome. Kaplan-Meier analysis, Cox models, restricted cubic splines (RCS), and subgroup analyses were performed to evaluate associations between RCII and mortality. Results: Among 11,917 CKM participants (median follow-up: 157 months), 2,474 all-cause and 774 cardiovascular deaths occurred. Elevated RCII was associated with increased mortality. In the fully adjusted model, each SD increase in RCII corresponded to a 7% higher risk of all-cause (HR = 1.07, 95% CI: 1.05-1.09) and 8% higher cardiovascular mortality (HR = 1.08, 95% CI: 1.05-1.12) (both Conclusions: Elevated RCII is strongly and consistently associated with increased all-cause and cardiovascular mortality risks among individuals with CKM. Further studies are warranted to validate its incremental predictive value and to explore targeted interventions for populations with high RCII.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.